Cargando…

Real-World Evaluation of Patiromer for the Treatment of Hyperkalemia in Hemodialysis Patients

INTRODUCTION: Patiromer is a potassium (K(+)) binding polymer indicated for treating hyperkalemia. Among patients receiving chronic hemodialysis (HD), this study aimed to identify patient characteristics associated with patiromer initiation, describe patiromer utilization, and analyze serum K(+) pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kovesdy, Csaba P., Rowan, Christopher G., Conrad, Ansgar, Spiegel, David M., Fogli, Jeanene, Oestreicher, Nina, Connaire, Jeffrey J., Winkelmayer, Wolfgang C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6365398/ https://www.ncbi.nlm.nih.gov/pubmed/30775627 http://dx.doi.org/10.1016/j.ekir.2018.10.020

Ejemplares similares

Cost-Effectiveness Analysis of Patiromer and Spironolactone Therapy in Heart Failure Patients with Hyperkalemia
por: Bounthavong, Mark, et al.
Publicado: (2018)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Clinical Efficacy, Safety, Tolerability, and Real-World Data of Patiromer for the Treatment of Hyperkalemia
por: Colbert, Gates, et al.
Publicado: (2022)

Serum-to-dialysate potassium gradient and its association with short-term outcomes in hemodialysis patients
por: Brunelli, Steven M, et al.
Publicado: (2018)

Assessment of Patiromer Monotherapy for Hyperkalemia in an Acute Care Setting
por: Di Palo, Katherine E., et al.
Publicado: (2022)

Patiromer induces rapid and sustained potassium lowering in patients with chronic kidney disease and hyperkalemia
por: Bushinsky, David A, et al.
Publicado: (2015)

Letter to the editor regarding ‘‘Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-analysis: Patiromer and Sodium Zirconium Cyclosilicate in Hyperkalemia’
por: Zarzuela, Donna, et al.
Publicado: (2021)

Effect of Patiromer in Hyperkalemic Patients Taking and Not Taking RAAS Inhibitors
por: Kloner, Robert A., et al.
Publicado: (2018)

Real-world evaluation of patiromer utilization and its effects on serum potassium in veterans with end stage kidney disease
por: Pinnell, Derek, et al.
Publicado: (2022)

Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization
por: Desai, Nihar R., et al.
Publicado: (2020)

Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics
por: Weir, Matthew R., et al.
Publicado: (2017)

Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial( )
por: Butler, Javed, et al.
Publicado: (2022)

Patiromer in a Patient with Severe Hyperkalemia on Incremental Hemodialysis with 1 Session per Week: A Case Report and Literature Review
por: De La Flor, José C., et al.
Publicado: (2021)

Patiromer and Sodium Zirconium Cyclosilicate in Treatment of Hyperkalemia: A Systematic Review and Meta-Analysis
por: Shrestha, Dhan Bahadur, et al.
Publicado: (2021)

A curious case of persistently relapsing hyperkalemia in an ESRD patient on maintenance hemodialysis following bioprosthetic aortic valve replacement – a potential case for the use of the new agent, patiromer, for hyperkalemia management
por: Onuigbo, Macaulay Amechi Chukwukadibia, et al.
Publicado: (2016)

New options for the management of chronic hyperkalemia
por: Fried, Linda, et al.
Publicado: (2017)

Pharmacodynamic effects of the K(+) binder patiromer in a novel chronic hyperkalemia model in spontaneously hypertensive rats
por: Iyer, Sai Prasad N., et al.
Publicado: (2020)

Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan
por: Kashihara, Naoki, et al.
Publicado: (2019)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review
por: Beccari, Mario V, et al.
Publicado: (2017)

Social determinants of patiromer adherence and abandonment: An observational, retrospective, real-world claims analysis
por: Kleinman, Nathan, et al.
Publicado: (2023)

Mechanism of Action and Pharmacology of Patiromer, a Nonabsorbed Cross-Linked Polymer That Lowers Serum Potassium Concentration in Patients With Hyperkalemia
por: Li, Lingyun, et al.
Publicado: (2016)

Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review [Erratum]
Publicado: (2019)

Evaluation of the Potential for Drug Interactions With Patiromer in Healthy Volunteers
por: Lesko, Lawrence J., et al.
Publicado: (2017)

NaPi-IIb Inhibition for Hyperphosphatemia in CKD Hemodialysis Patients
por: Maruyama, Sonomi, et al.
Publicado: (2020)

Course of Hyperkalemia in Patients on Hemodialysis
por: Spinowitz, Bruce, et al.
Publicado: (2022)

Assessing patiromer utilization and associated serum potassium changes in US veterans with prior sodium polystyrene sulfonate exposure
por: Patel, Shardool, et al.
Publicado: (2023)

The burden of hyperkalemia in Germany – a real world evidence study assessing the treatment and costs of hyperkalemia
por: Haas, Jennifer Scarlet, et al.
Publicado: (2020)

Effects of different potassium-lowering regimens on acute hyperkalemia in hemodialysis patients: a real-world, retrospective study
por: Yao, Lan, et al.
Publicado: (2022)

Patiromer sorbitex calcium for hyperkalaemia
Publicado: (2019)

A Real-World Experience of Hyperkalemia Management Using Sodium Zirconium Cyclosilicate in Chronic Hemodialysis: A Multicenter Clinical Audit
por: Qu, XiaoJie, et al.
Publicado: (2023)

Case report: Patiromer-induced hypercalcemia
por: Wiederkehr, Michael R., et al.
Publicado: (2019)

Real-World Assessment of Health Care Costs for Patients with Metastatic Pancreatic Cancer Following Initiation of First-Line Chemotherapy
por: Bullock, Andrea, et al.
Publicado: (2020)

Cost-Effectiveness of Treating Patients with Chronic Kidney Disease and Prior Hyperkalemia with Renin–Angiotensin–Aldosterone System Inhibitor and Patiromer: A Swiss Public Healthcare Perspective
por: Fischer, Barbara, et al.
Publicado: (2022)

Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes
por: Khanagavi, Jagadish, et al.
Publicado: (2014)

Residual Kidney Function and Cause-Specific Mortality Among Incident Hemodialysis Patients
por: Okazaki, Masaki, et al.
Publicado: (2023)

Safety and Tolerability of the Potassium Binder Patiromer From a Global Pharmacovigilance Database Collected Over 4 Years Compared with Data from the Clinical Trial Program
por: Rossignol, Patrick, et al.
Publicado: (2021)

Experience with the potassium binder patiromer in hyperkalaemia management in heart failure patients in real life
por: Esteban‐Fernández, Alberto, et al.
Publicado: (2022)

Hyperkalemia in patients undergoing hemodialysis: Its pathophysiology and management
por: Shibata, Shigeru, et al.
Publicado: (2021)

A Rare Case of Patiromer Induced Hypercalcemia
por: Kanduri, Swetha Rani, et al.
Publicado: (2021)

The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review
por: Bem, Danai, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9vn2qrgnbsf30n9kjrm0cjp7g0